Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169780 | 0.77 | — | — | |
| SCHEMBL28925316 | 0.76 | KDM4E (0.39) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL474704 | 0.74 | HDAC3 (0.36) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4600005 | 0.74 | PRMT5 (0.36) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9686056 | 0.72 | CYP3A4 (0.37) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8522972 | 0.70 | CYP3A4 (0.35) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9081577 | 0.70 | — | — | |
| SCHEMBL16178834 | 0.69 | — | — | |
| SCHEMBL28232194 | 0.69 | PIK3CD (0.40) | — | |
| SCHEMBL31632721 | 0.68 | NAAA (0.45) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215888-A1 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2009-08-27 | — | — | US | claimed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | claimed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | claimed |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-3595633-B1 | TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANES | DFB SORIA LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | DFB SORIA, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-11583499-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230038716-A1 | TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND CERVICAL CANCER USING NANOPARTICLES OF TAXANES | DFB SORIA, LLC | 2023-02-09 | — | — | US | disclosed |
| US-11331278-B2 | Delivery of drug nanoparticles and methods of use thereof | DFB SORIA, LLC (US) | 2022-05-17 | — | — | US | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| WO-2005012549-A2 | APPARATUS AND METHODS FOR EVALUATING THE BARRIER PROPERTIES OF A MEMBRANE | FQUBED, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040229930-A1 | Formulations comprising a basic indolinone compound | PHARMACIA ITALIA S.P.A. | 2004-11-18 | — | — | US | disclosed |
| WO-2004024127-A2 | SOLID FORMULATIONS COMPRISING AN INDOLINONE COMPOUND | PHARMACIA ITALIA S.P.A. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040023841-A1 | Combinatorial method for rapid screening of drug delivery formulations | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2004-02-05 | — | — | US | disclosed |
| EP-1233943-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | Sugen, Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | CYP3A4 4854/4885HDAC3 644/4885HDAC4 1156/4885 |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | KRT18, TUBB3, TUBA3E | CYP3A4 4316/4885HDAC3 3978/4885HDAC4 3299/4885 |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | CYP3A4 4854/4885HDAC3 644/4885HDAC4 1156/4885 |
| US-20230038716-A1 | TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND CERVICAL CANCER USING NANOPARTICLES OF TAXANES | NCL, HUNK, LMNB1 | CYP3A4 4280/4885HDAC3 2459/4885HDAC4 1181/4885 |
| US-20040229930-A1 | Formulations comprising a basic indolinone compound | PDPK1, HASPIN, IP6K1 | CYP3A4 667/4885HDAC3 1621/4885HDAC4 1466/4885 |
| US-11331278-B2 | Delivery of drug nanoparticles and methods of use thereof | VCL, BRCA1, KRT18 | CYP3A4 2708/4885HDAC3 2970/4885HDAC4 3347/4885 |
| US-11583499-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | CYP3A4 4794/4885HDAC3 2768/4885HDAC4 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.